Loading organizations...
Based in Boston, Massachusetts, Ankyra Therapeutics is a clinical-stage biotechnology company developing anchored-drug conjugates that localize immunotherapies within the tumor microenvironment to treat advanced solid tumors. The company utilizes a proprietary platform to bind immune-stimulating molecules to aluminum hydroxide, which prolongs anti-tumor immune activation while minimizing systemic side effects from drug leakage. Following FDA clearance of its investigational new drug application, the enterprise successfully dosed the first patient in a Phase 1 clinical trial for its lead candidate, ANK-101, in late 2023. The pre-revenue biotechnology startup has raised $45 million in total Series B funding, reaching an estimated post-money valuation of $150.98 million with backing from prominent institutional investors including Polaris Partners, GV, Sanofi Ventures, and MRL Ventures Fund. Ankyra Therapeutics was originally founded in 2019 by bioengineers Darrell Irvine, Karl Wittrup, and Tillman Gerngross.
Ankyra has raised $45.0M across 1 funding round.
Ankyra has raised $45.0M in total across 1 funding round.
Ankyra Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, developing anchored-drug conjugate technologies to expand the therapeutic window of immunotherapies for cancer and other serious diseases.[1][2][5] Its core platform creates stable drug depots via local administration, enabling prolonged immune activation with reduced systemic toxicity, and its lead candidate, ANK-101 (an IL-12 anchored-drug conjugate), is in Phase 1 trials for advanced solid tumors, with recent expansion into non-small cell lung cancer (NSCLC) via a Johnson & Johnson collaboration.[2][5] The company serves patients with solid tumors by addressing limitations in existing immunotherapies, such as dose-limiting toxicities, through tumor-retaining molecules bound to aluminum hydroxide, showing strong preclinical efficacy with single-dose activity.[1][5]
Ankyra Therapeutics emerged as a biotech focused on innovative immunotherapy delivery, though specific founding year and founders are not detailed in available sources; its team collectively has experience bringing seven drugs to global market approval, emphasizing practical execution.[3][5] Key leadership includes CEO Howard L. Kaufman, MD, who highlighted strategic hires like the recent Chief Scientific Officer Sailaja Battula, PhD (with over a decade in immuno-oncology from roles at Immuneering and Bicycle Therapeutics), alongside executives such as CFO Stephen Gorgol, CMO Joseph Elassal, CSO Robert Tighe, and Chief Process Officer Greg Zarbis-Papastoitsis.[1][4] Pivotal early momentum includes advancing ANK-101 to Phase 1 trials after robust preclinical results and securing an expanded collaboration with Johnson & Johnson in early 2025 to test in NSCLC.[2][5]
Ankyra rides the immunotherapy expansion trend in oncology, targeting unmet needs in solid tumors where systemic toxicities limit drugs like IL-12, amid rising demand for localized, sustained-release therapies.[1][5] Timing aligns with advances in drug conjugates and bispecifics, bolstered by market forces like NSCLC prevalence (most common lung cancer) and big pharma interest, as seen in its Johnson & Johnson deal.[2] It influences the ecosystem by pioneering tumor-anchored platforms, potentially enabling broader immunotherapy adoption and reducing treatment burdens.[5]
Ankyra's near-term focus will likely center on ANK-101 Phase 1 data readouts, pipeline expansion under new CSO leadership, and deepening pharma collaborations to accelerate toward approvals.[1][2] Trends like precision oncology and next-gen conjugates will shape its path, with success hinging on clinical safety-efficacy balance in NSCLC and beyond. Its influence could grow by validating anchored tech as a standard for safer immunotherapies, transforming how biotech tackles tumor-localized treatments—building on its promise to expand immunotherapy's therapeutic window.[5]
Ankyra has raised $45.0M across 1 funding round. Most recently, it raised $45.0M Series B in November 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2021 | $45M Series B | — | Kevin Hartz, Alumni Ventures, Atomico, Borealis Ventures, Krishna Yeshwant, Mithril Capital Management, Polaris Partners, RA Capital, Julia Hartz, TOM Blomfield, Fidelity Management & Research Company, GV, Polaris Partners, Sands Capital | Announced |
Ankyra has raised $45.0M in total across 1 funding round.
Ankyra's investors include Kevin Hartz, Alumni Ventures, Atomico, Borealis Ventures, Krishna Yeshwant, Mithril Capital Management, Polaris Partners, RA Capital, Julia Hartz, Tom Blomfield, Fidelity Management & Research Company, Google Ventures.
